Interius BioTherapeutics

Recent Finacing

Series A

Recent Raise

$76M

Interius BioTherapeutics develops an in vivo, cell-specific gene-delivery platform to generate CAR T cells directly in patients, avoiding ex vivo cell manipulation and pre-conditioning chemotherapy, with applications beyond oncology.

Founded 2019

Pennsylvania, United States

11-50

Private

interiusbio.com

Highlights

Focus Areas

Biopharma

Biotechnology

Health Care

Therapeutics

Recent Investors

K

Financials

$76M

Total Raised

1

Funding round

16

Investors

Team

Upgrade to view the team

See the team members at Interius BioTherapeutics.